This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.
DNA Damage Response (DDR) and Antibody Drug Conjugate (ADC) scientific platforms.
The drug is an HER2-directed antibody drug conjugate (ADC) and is a treatment option for adult patients in the US living with unresectable or metastatic breast HER2-positive breast cancer
However, recent developments in the use of antibody-drug conjugates (ADC) involving trastuzumab are offering hope to women with metastatic breast cancer. ... These include data from AstraZeneca’s DESTINY-Breast03 phase 3 trial that showed its ADC
Enhertu is a HER2-directed antibody drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo that has now been granted four Breakthrough Therapy Designations, including two in breast cancer.
Tivdak – which was granted priority review by the FDA in April – is an antibody-drug conjugate composed of Genmab’s human monoclonal antibody and Seagen’s ADC technology involving monomethyl auristatin ... The ADC is directed to tissue factor, a
The ADC Therapeutics antibody-drug conjugate is licensed to treat patients with a common form of non-Hodgkin lymphoma. ... In August, ADC entered into a financing agreement with healthcare investment firm HealthCare Royalty Partners.
More from news
Approximately 3 fully matching, plus 92 partially matching documents found.
One such example is through the development of antibody-drug conjugates (ADC) – monoclonal antibodies attached to biologically active cytotoxic drugs. ... The FDA recently granted accelerated approval for the ADC trastuzumab-deruxtecan in patients with
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2. ... Kadcyla, the only other anti-HER2 ADC in this market, is a direct competitor and differentiation versus this established drug will be key.
The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Roche already has a
In addition to traditional antibodies, the pipeline also includes antibody drug conjugates (ADCs), bispecific antibodies created from its DuoBody technology platform, and antibodies created with its HexaBody technology.
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... As an ADC IMMU-132 contains SN-38,
More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.
Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s
His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product
Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:
These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.
conjugates (ADCs) for cancer.
More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.
Pegasus –the fifth largest healthcare agency in the UK –has merged with fellow Ashfield Health agencies Ashfield Digital and Creative (ADC) and Cambridge Biomarketing to form Mind Matter, a ‘global creative
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...